25 / 32
Cut-off date: 31 May 2018
Note: Patients (n=6) without matched pre/post therapy scans were excluded from the plot
CI: confidence interval; CRC: colorectal cancer;
MASC: mammary analogue secretory carcinoma;
NSCLC: non-small cell lung cancer
tumours: individual patient responses by tumour type
0
-30
-50
-90
Best % change from baseline
15
-80
-70
-60
-40
-20
-10
20
30
40
-100
50
CRC
NSCLC
Sarcoma
Neuroendocrine tumours
Pancreatic
Thyroid
MASC Breast
Cholangiocarcinoma
Gynaecological
NTRK
+ patients (n=54)
ORR (95% CI)
57.4%
(43.2–70.8)
SD
9 (16.7)
PD
4 (7.4)
Non-CR/PD, missing or unevaluable
10 (18.5)
Results per Blinded Independent Central Review (BICR)